The association between childhood asthma and adult chronic obstructive pulmonary disease

Tai, Andrew; Tran, Haily; Roberts, Mary Flynn; Clarke, Nadeene; Wilson, John W.; Robertson, Colin F.

doi:10.1136/thoraxjnl-2013-204815

Cited by 266 publications

(202 citation statements)

References 36 publications

Supporting

Mentioning

190

Contrasting

Unclassified

Order By: Relevance

“…They comprised 6 birth cohorts [17][18][19][20][21][22] and 19 population-based longitudinal studies. [12,13,[23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39] Tables 1 and 2 give an overview of the included studies. The reasons for rejecting the remaining 30 papers [9,10, are summarised in Table 3.…”

Section: Resultsmentioning

confidence: 99%

“…[12,13] The vast majority of those with COPD aged 50 years came from the severe asthma group recruited at 10 years of age.…”

Section: Page 13 Of 24mentioning

confidence: 99%

“…[11] The assumption that children with reduced lung function will continue to have poor respiratory health is supported by the Melbourne Asthma Cohort in that those with severe asthma added to the study at the age of 10 years already then demonstrating low lung function, were much more likely to develop COPD by 55 years of age. [12,13] A c c e p t e d M a n u s c r i p t 4 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A systematic review of early life factors which adversely affect subsequent lung function

Kouzouna

Gilchrist

Ball

et al. 2016

Paediatric Respiratory Reviews

View full text Add to dashboard Cite

It has been known for many years that multiple early life factors can adversely affect lung function and future respiratory health. This is the first systematic review to attempt to analyse all these factors simultaneously. We adhered to strict a priori criteria for inclusion and exclusion of studies.The initial search yielded 29,351 citations of which 208 articles were reviewed in full and 25 were included in the review. This included 6 birth cohorts and 19 longitudinal population studies. The 25 studies reported the effect of 74 childhood factors (on their own or in combinations with other factors) on subsequent lung function reported as percent predicted forced expiration in one second (FEV 1 ). The childhood factors that were associated with a significant reduction in future FEV 1 could be grouped as: early infection, bronchial hyper-reactivity (BHR) / airway lability, a diagnosis of asthma, wheeze, family history of atopy or asthma, respiratory symptoms and prematurity / low birth weight. A complete mathematical model will only be possible if the raw data from all previous studies is made available. This highlights the need for increased cooperation between researchers and the need for international consensus about the outcome measures for future longitudinal studies.

show abstract

Section: Resultsmentioning

confidence: 99%

“…[12,13] The vast majority of those with COPD aged 50 years came from the severe asthma group recruited at 10 years of age.…”

Section: Page 13 Of 24mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review of early life factors which adversely affect subsequent lung function

Kouzouna

Gilchrist

Ball

et al. 2016

Paediatric Respiratory Reviews

View full text Add to dashboard Cite

show abstract

“…Studies involving children and young adults have shown that the most important determinant of maximally attained lung function later in life was the lung-function value at a younger age. [26][27][28][29] Svanes et al observed that childhood risk factors such as maternal smoking, childhood respiratory infections, and childhood asthma were strongly related to the development of COPD in young adults. 30 Nevertheless, although our results highlight the important role of maximally attained lung function in early adulthood, Shown is the distribution of observed annual decline in forced expiratory volume in 1 second (FEV 1 ) among 2864 participants in the Framingham Offspring Cohort (FOC) and the Copenhagen City Heart Study (CCHS), according to the four trajectories defined on the basis of a normal FEV 1 (≥80% of the predicted value) or low FEV 1 (<80% of the predicted value) at baseline and the presence or absence of chronic obstructive pulmonary disease (COPD) at the final examination.…”

Section: Discussionmentioning

confidence: 99%

Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease

et al. 2015

View full text Add to dashboard Cite

BACKGROUNDChronic obstructive pulmonary disease (COPD) is thought to result from an accelerated decline in forced expiratory volume in 1 second (FEV 1 ) over time. Yet it is possible that a normal decline in FEV 1 could also lead to COPD in persons whose maximally attained FEV 1 is less than population norms. METHODSWe stratified participants in three independent cohorts (the Framingham Offspring Cohort, the Copenhagen City Heart Study, and the Lovelace Smokers Cohort) according to lung function (FEV 1 ≥80% or <80% of the predicted value) at cohort inception (mean age of patients, approximately 40 years) and the presence or absence of COPD at the last study visit. We then determined the rate of decline in FEV 1 over time among the participants according to their FEV 1 at cohort inception and COPD status at study end. RESULTSAmong 657 persons who had an FEV 1 of less than 80% of the predicted value before 40 years of age, 174 (26%) had COPD after 22 years of observation, whereas among 2207 persons who had a baseline FEV 1 of at least 80% of the predicted value before 40 years of age, 158 (7%) had COPD after 22 years of observation (P<0.001). Approximately half the 332 persons with COPD at the end of the observation period had had a normal FEV 1 before 40 years of age and had a rapid decline in FEV 1 thereafter, with a mean (±SD) decline of 53±21 ml per year. The remaining half had had a low FEV 1 in early adulthood and a subsequent mean decline in FEV 1 of 27±18 ml per year (P<0.001), despite similar smoking exposure. CONCLUSIONSOur study suggests that low FEV 1 in early adulthood is important in the genesis of COPD and that accelerated decline in FEV 1 is not an obligate feature of COPD. (Funded by an unrestricted grant from GlaxoSmithKline and others.) a bs tr ac t

show abstract

“…To muddy the waters further, the presence of fixed airways obstruction is not uncommon among nonsmokers [108,109]. A proportion of these cases are probably untreated asthma, the result of airway remodelling in chronic asthma despite treatment or of severe childhood asthma [110,111]. In the recent BOLD (Burden of Obstructive Lung Disease) initiative [112], the occurrence of post-bronchodilator airflow limitation found during screening of population-based samples has been termed COPD, regardless of potential aetiological factors such as smoking, asthma or childhood respiratory disease.…”

Section: Copd Phenotypes or How To Predict Which Patients Benefit Fromentioning

confidence: 99%

Inhaled corticosteroids in COPD: the clinical evidence

2014

View full text Add to dashboard Cite

In this article, we focus on the scientific evidence from randomised trials supporting treatment with inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD), including treatment with combinations of long-acting β-agonist (LABA) bronchodilators and ICS. Our emphasis is on the methodological strengths and limitations that guide the conclusions that may be drawn.The evidence of benefit of ICS and, therefore, of the LABA/ICS combinations in COPD is limited by major methodological problems. From the data reviewed herein, we conclude that there is no survival benefit independent of the effect of long-acting bronchodilation and no effect on FEV1 decline, and that the possible benefit on reducing severe exacerbations is unclear. Our interpretation of the data is that there are substantial adverse effects from the use of ICS in patients with COPD, most notably severe pneumonia resulting in excess deaths.Currently, the most reliable predictor of response to ICS in COPD is the presence of eosinophilic inflammation in the sputum. There is an urgent need for better markers of benefit and risk that can be tested in randomised trials for use in routine specialist practice. Given the overall safety and effectiveness of long-acting bronchodilators in subjects without an asthma component to their COPD, we believe use of such agents without an associated ICS should be favoured. @ERSpublicationsThe benefits of ICS in COPD are limited. Better tools are needed to identify which patients might benefit.

show abstract

The association between childhood asthma and adult chronic obstructive pulmonary disease

Cited by 266 publications

References 36 publications

A systematic review of early life factors which adversely affect subsequent lung function

A systematic review of early life factors which adversely affect subsequent lung function

Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease

Inhaled corticosteroids in COPD: the clinical evidence

Contact Info

Product

Resources

About